Shattuck Labs ends silence with a shout-out on $118M raise for fusion protein work
After four years of relative obscurity in a residential Austin neighborhood, Shattuck Labs has emerged with $118 million from Redmile Group and over 10 other investors.
Co-founded in 2016 by CEO Taylor Schreiber, an immunologist and a lymphoma survivor, the startup announced an immuno-oncology partnership with Takeda the next year, but kept an otherwise low profile. SEC records indicate they raised a $46 million Series A in 2018, but they never put out a press release.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.